全文获取类型
收费全文 | 10412篇 |
免费 | 1163篇 |
国内免费 | 296篇 |
专业分类
耳鼻咽喉 | 94篇 |
儿科学 | 157篇 |
妇产科学 | 53篇 |
基础医学 | 458篇 |
口腔科学 | 19篇 |
临床医学 | 814篇 |
内科学 | 689篇 |
皮肤病学 | 122篇 |
神经病学 | 905篇 |
特种医学 | 505篇 |
外科学 | 484篇 |
综合类 | 1406篇 |
预防医学 | 211篇 |
眼科学 | 4612篇 |
药学 | 790篇 |
2篇 | |
中国医学 | 434篇 |
肿瘤学 | 116篇 |
出版年
2024年 | 34篇 |
2023年 | 217篇 |
2022年 | 290篇 |
2021年 | 473篇 |
2020年 | 462篇 |
2019年 | 363篇 |
2018年 | 461篇 |
2017年 | 427篇 |
2016年 | 428篇 |
2015年 | 386篇 |
2014年 | 626篇 |
2013年 | 863篇 |
2012年 | 605篇 |
2011年 | 609篇 |
2010年 | 489篇 |
2009年 | 485篇 |
2008年 | 588篇 |
2007年 | 537篇 |
2006年 | 501篇 |
2005年 | 455篇 |
2004年 | 302篇 |
2003年 | 284篇 |
2002年 | 202篇 |
2001年 | 202篇 |
2000年 | 176篇 |
1999年 | 164篇 |
1998年 | 140篇 |
1997年 | 109篇 |
1996年 | 90篇 |
1995年 | 101篇 |
1994年 | 93篇 |
1993年 | 61篇 |
1992年 | 69篇 |
1991年 | 45篇 |
1990年 | 47篇 |
1989年 | 46篇 |
1988年 | 53篇 |
1987年 | 38篇 |
1986年 | 32篇 |
1985年 | 66篇 |
1984年 | 55篇 |
1983年 | 31篇 |
1982年 | 35篇 |
1981年 | 28篇 |
1980年 | 30篇 |
1979年 | 15篇 |
1978年 | 23篇 |
1977年 | 14篇 |
1976年 | 5篇 |
1975年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Survey of ophthalmology》2023,68(5):920-928
There remains limited agreement regarding the efficacy and safety of different antivascular endothelial growth factor (anti-VEGF) agents for the management of polypoidal choroidal vasculopathy (PCV). Our meta-analysis compares different anti-VEGF agents for PCV treatment. Ovid MEDLINE, EMBASE, and Cochrane Library were systematically searched from January 2000 to July 2022. We included articles comparing the efficacy and safety of different anti-VEGF agents, specifically bevacizumab (BEV), ranibizumab (RAN), aflibercept AFL), and brolucizumab (BRO), for patients with PCV. 10,440 studies were identified, 122 underwent full-text review, and seven were included. One study was a randomized trial, and six were observational studies. Ranibizumab and aflibercept were associated with a similar best-corrected visual acuity (BCVA) at the last visit in three observational studies (P = 0.10), similar retinal thickness at the last visit in two observational studies (P = 0.85). One observational study comparing BEV versus RAN found comparable outcomes for final BCVA, retinal thickness, and polyp regression. One randomized trial on BRO versus AFL found comparable outcomes for improvement in BCVA, while anatomical outcomes favored BRO. The available evidence suggests that final BCVA is comparable across different anti-VEGF agents, however, further investigation is warranted due to paucity of evidence. 相似文献
2.
3.
4.
5.
6.
7.
Diabetic macular ischaemia (DMI) is traditionally defined and graded based on the angiographic evidence of an enlarged and irregular foveal avascular zone. However, these anatomical changes are not surrogate markers for visual impairment. We postulate that there are vascular phenotypes of DMI based on the relative perfusion deficits of various retinal capillary plexuses and choriocapillaris. This review highlights several mechanistic pathways, including the role of hypoxia and the complex relation between neurons, glia, and microvasculature. The current animal models are reviewed, with shortcomings noted. Therefore, utilising the advancing technology of optical coherence tomography angiography (OCTA) to identify the reversible DMI phenotypes may be the key to successful therapeutic interventions for DMI. However, there is a need to standardise the nomenclature of OCTA perfusion status. Visual acuity is not an ideal endpoint for DMI clinical trials. New trial endpoints that represent disease progression need to be developed before irreversible vision loss in patients with DMI. Natural history studies are required to determine the course of each vascular and neuronal parameter to define the DMI phenotypes. These DMI phenotypes may also partly explain the development and recurrence of diabetic macular oedema. It is also currently unclear where and how DMI fits into the diabetic retinopathy severity scales, further highlighting the need to better define the progression of diabetic retinopathy and DMI based on both multimodal imaging and visual function. Finally, we discuss a complete set of proposed therapeutic pathways for DMI, including cell-based therapies that may provide restorative potential. 相似文献
8.
9.
10.